A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.

MLA

Desai, Kunal B., et al. “A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 11, June 2024, pp. 2384–92. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-23-3636.

APA

Desai, K. B., Serritella, A. V., Stadler, W. M., O’Donnell, P. H., Sweis, R. F., & Szmulewitz, R. Z. (2024). A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 30(11), 2384–2392. https://doi.org/10.1158/1078-0432.CCR-23-3636

Chicago

Desai, Kunal B, Anthony V Serritella, Walter M Stadler, Peter H O’Donnell, Randy F Sweis, and Russell Z Szmulewitz. 2024. “A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30 (11): 2384–92. doi:10.1158/1078-0432.CCR-23-3636.